Generate Biomedicines has completed its IPO, raising an impressive $400 million that makes it the largest listing for a biotech on the Nasdaq so far this year. Incubated by investment group Flagship ...

Data work in 2026 asks for more than chart building. Professionals are expected to clean data, query databases, explain ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generate:Biomedicines raised ...

Generate Biomedicines Inc. filed for an initial public offering, joining a growing list of biotechnology firms to leap to public markets as investors embrace the sector. The Somerville, ...

Grok, the AI chatbot on Elon Musk’s social media platform X, is limiting image generation and editing capabilities to paying subscribers amid a global outcry from officials and users over the tool ...

I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

The benchmarks are quite simple and consist of generating IDs using each library's raw interface as much as possible, e.g. the UUID module is benchmarked by measuring the execution time of the ...